Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18142 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von James Lok. Beteiligte Einrichtung: Institute of Liver Studies, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18174
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Liver Studies, King's College Hospital, London, UK.
ORCID-Profile: James Lok
Zitieren
APA
Lok, J. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18142
Vancouver
Lok J. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18142
BibTeX
@article{Lok2024,
author = {Lok, James},
title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18142}
}
EUVIMED